CAS 1221573-85-8

Paritaprevir

Description:

Paritaprevir is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It belongs to the class of drugs known as protease inhibitors, specifically targeting the NS3/4A protease enzyme, which is crucial for viral replication. Paritaprevir is often administered in combination with other antiviral agents to enhance its efficacy and reduce the likelihood of resistance. The compound is characterized by its specific molecular structure, which includes a series of functional groups that contribute to its biological activity and solubility. It is typically formulated as part of a fixed-dose combination therapy, often alongside ombitasvir and ritonavir, to improve patient adherence and treatment outcomes. Paritaprevir is generally well-tolerated, but like all medications, it may have side effects, including potential liver enzyme elevations. Its pharmacokinetics involve metabolism primarily through the liver, necessitating careful monitoring in patients with hepatic impairment. Overall, Paritaprevir represents a significant advancement in the management of chronic hepatitis C.

Formula: C₄₀H₄₃N₇O₇S

InChI: InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1

InChI key: InChIKey=UAUIUKWPKRJZJV-QPLHLKROSA-N

SMILES: C(NS(=O)(=O)C1CC1)(=O)[C@]23[C@@](C2)(/C=C\CCCCC[C@H](NC(=O)C=4C=NC(C)=CN4)C(=O)N5[C@](C(=O)N3)(C[C@@H](OC6=C7C(=C8C(=N6)C=CC=C8)C=CC=C7)C5)[H])[H]

Synonyms:

• Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-
• (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
• Paritaprevir
• ABT 450
• Veruprevir
• PubChem ID: 45110509

Paritaprevir free base

CAS: 1221573-85-8

Paritaprevir free base

Purity: ≥95%

Molecular weight: 765.89g/mol

Ref: 54-BUP02293

Paritaprevir free base

CAS: 1221573-85-8

Paritaprevir (ABT-450) is an oral HCV NS3/NS4A protease inhibitor with potential against genotype 1, disrupting viral replication.

Formula: C₄₀H₄₃N₇O₇S

Purity: 95% - 99.26%

Color and Shape: Solid

Molecular weight: 765.89

Ref: TM-T3226

Paritaprevir

CAS: 1221573-85-8

Paritaprevir is a medicinal compound that acts as an inhibitor of protein kinases. It has been shown to be effective against various types of cancer cells, including those found in the urine and tumors. Paritaprevir is an analog of a Chinese anticancer compound and has been shown to induce apoptosis in human cancer cells. This potent kinase inhibitor selectively targets specific kinases involved in cancer cell proliferation, making it a promising candidate for the treatment of cancer. Its ability to inhibit kinases also makes it an attractive therapeutic option for other diseases that involve aberrant kinase activity.

Formula: C₄₀H₄₃N₇O₇S

Purity: Min. 95%

Molecular weight: 765.9 g/mol

Ref: 3D-WYB57385